Massachusetts General Hospital: Lymphoma trials

The registry lists 32 Lymphoma studies with Massachusetts General Hospital as lead sponsor. 4 are open to participants now and 19 have results posted.

Phase 1 7Phase 2 18No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingNCT07711483Phase 2
• Increasing Resiliency Among Early Post-Treatment Lymphoma SurvivorsRecruitingNCT07014293Not applicable
• A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma SurvivorshipRecruitingNCT07013435Not applicable
• Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular TherapyRecruitingNCT05646576Not applicable
• Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)CompletedNCT06004167Not applicableResults posted
• Radiation Post-CAR T in Refractory LymphomaTerminatedNCT04473937Not applicableResults posted
• Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT03919175Phase 2Results posted
• Promoting Resiliency Among Lymphoma Survivors: The 3RP-LymphomaCompletedNCT03212261Not applicableResults posted
• A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin LymphomaTerminatedNCT02811679Phase 2Results posted
• Meloxicam vs Placebo for MobilizationCompletedNCT02003625Phase 2Results posted
• Proton Radiation for Lymphoma Involving MediastinumTerminatedNCT01751412Not applicableResults posted
• Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaCompletedNCT01534078Phase 2Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT01282476Phase 2Results posted
• Ofatumumab for Initial Systemic Treatment of Indolent B-cell LymphomaCompletedNCT01239394Phase 2Results posted
• High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) LymphomaCompletedNCT01182415Phase 2Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
• High Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasCompletedNCT00895661Phase 2Results posted
• Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT00869999Phase 2Results posted
• Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin LymphomaTerminatedNCT00722865Phase 2Results posted
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Supportive Oncology Care At Home RCTActive, not recruitingNCT04544046Not applicable
• Home Hospital for LymphomaTerminatedNCT04423848Not applicable
• Lorlatinib Combinations in Lung CancerStatus unknownNCT04292119Phase 1/2
• Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For LymphomaWithdrawnNCT02724904Phase 1/2
• Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
• Cardiac Fibrosis by CMR in Patients With CancerWithdrawnNCT01906437
• Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
• Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)CompletedNCT00916630Phase 1
• CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT00455897Phase 2